Clinical Trials Logo

Vascular Complications clinical trials

View clinical trials related to Vascular Complications.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05220540 Completed - Clinical trials for Vascular Complications

Retrospective Analysis of Balloon Expandable Covered Stenting in the Common Femoral Artery

BEST-CFA
Start date: January 1, 2010
Phase:
Study type: Observational

The aim of this study is to evaluate the safety and efficacy of balloon expandable covered stenting of access complications, stenoses or pseudoaneurysms of the common femoral access.

NCT ID: NCT05031936 Completed - Clinical trials for Vascular Complications

: Intravascular Injection Rates During Cervical Medial Branch Block

Start date: August 12, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare using Toughy needle has an advantage of reducing intravascular injection rates during cervical medial branch block.

NCT ID: NCT04363021 Completed - Preeclampsia Clinical Trials

Is a History of Pre-eclampsia a Risk Factor for Vascular Phenotype in Women With Systemic Sclerosis?

PREVASCLERO
Start date: July 6, 2020
Phase:
Study type: Observational

Background: Pre-eclampsia, defined by the association of an arterial hypertension and significant proteinuria after 20 weeks of gestation, complicates 1 to 2% of pregnancies in France. Its pathophysiology involves angiogenesis impairment, upregulated maternal systemic inflammatory response, activation of oxidative stress and endothelial dysfunction. In a recent Danish nation-wide cohort study, pre-eclampsia was associated with a 69% increased risk of later developing scleroderma. Type of study: prospective observational case-control study. Primary objective of the study: to determine if a history of pre-eclampsia before systemic sclerosis diagnosis is an independent risk factor for vascular phenotype in sclerodermic women. Secondary objective: to describe all risk factors for vascular phenotype in sclerodermic women with a previous pregnancy longer than 6 months before scleroderma diagnosis.